"Clinicians Guide to Anti-inflammatory Treatments for Major Depression" - Savannah Demko
Targeting inflammation is a promising way to treat patients with major depressive disorder, according to a report by researchers at the Icahn School of Medicine and published in the Journal of Clinical Psychiatry. “Prior research has shown a link between inflammation and greater depressive symptom severity as well as resistance to commonly used antidepressants in major depressive disorder,” said Manish Kumar Jha, MD, assistant professor of psychiatry and neuroscience at the Icahn School of Medicine at Mount Sinai. “Adjunctive celecoxib, the most widely studied NSAID for its antidepressant effect, was linked to higher rates of remission compared with placebo in a prior meta-analysis, but using celecoxib along with antidepressants was also discouraged in another prior report. NSAIDs also have poor clinical utility as antidepressant monotherapy.”
— Manish Kumar Jha, MD, Assistant Professor, Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai